Rezatapopt and azacitidine for AML or MDS with a specific TP53 mutation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back after treatment (relapsed) or did not respond to prior treatment (refractory).
- Your cancer cells must have a specific change in the TP53 gene called Y220C. This must be confirmed by a standard lab test, and the change must be present in more than 2% of the cells tested.
- You must be able to take care of yourself and be up and about at least half of the day (ECOG score 0-2).
- Your liver and kidney function must be within certain limits, as determined by blood tests.
- If you could become pregnant, you must have a negative pregnancy test and agree to use effective birth control during the study and for a few months after.
- You cannot have received certain cancer treatments within 14 days before starting the study drugs.
- You cannot have certain active infections (like HIV, hepatitis B or C) or other serious medical conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining a new drug called ATRN-119 with a cancer medicine called decitabine can help patients with acute myeloid leukemia (AML) or a related bone marrow condition called high-risk myelodysplastic syndrome (MDS), especially those whose cancer cells have changes in a gene called TP53. The trial is looking for patients who have not responded to or cannot tolerate standard treatments.
This trial tests a new combination of drugs (axatilimab, decitabine, and venetoclax) for people with a specific type of acute myeloid leukemia (AML) that has a change in the TP53 gene. The goal is to see if this treatment can help when standard treatments haven't worked or for newly diagnosed patients with this genetic change.
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
This trial tests a combination of two drugs—ropeginterferon (an immune-boosting protein) and azacitidine (a cancer-fighting medicine)—in adults newly diagnosed with myelodysplastic syndrome or acute myeloid leukemia who have a specific genetic change (TP53 mutation). The goal is to help patients who cannot tolerate intensive chemotherapy.
This trial tests a new drug called APG1252 combined with azacitidine (AZA) for people with high-risk AML or certain related blood cancers. The goal is to see if the combination works better than standard treatments.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.